Biomarker-Based Strategies for Optimizing Adrenal Insufficiency Management

Overview

About this study

The purpose of this research study is to identify biomarkers at baseline and determine if the Oura Ring can optimize adrenal insufficiency management by tracking symptoms and predicting periods of illness. The data will be obtained from two groups: patients diagnosed with adrenal insufficiency and patients without adrenal insufficiency (control group).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  • Adults, 18 years or older, with PAI or adults without PAI (referent population)
  • Stable glucocorticoid and mineralocorticoid regimen in the last 6 weeks and no plans to change the regimen within the 4 weeks post-visit (outside from stress dosing)
  • Patient provided smartphone and ability to access and use internet/email.
  • iOS devices running Apple iOS 15 and higher, or Android devices running Android 9 and higher. Device must support Bluetooth 4.0
  • Willing to wear Oura ring for a minimum of 6 months and maximum of duration of the study/duration of ring function, particularly at night/while sleeping. Open Oura app daily (data syncing).
  • Willing to participate in baseline procedures.
  • Willing to complete redcap collection form to document symptoms, glucocorticoid dose changes, and medical events.
  • Willing to complete longitudinal redcap forms on quality of life, sleep, and cognition.

Exclusion criteria:

  • Glucocorticoid injection within the last 6 weeks from baseline assessment.
  • Glucocorticoid other than hydrocortisone and prednisone.
  • Pregnancy at baseline visit.
  • PI decision of ineligibility due to medication/comorbidity/other.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/27/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D., M.S.

Contact us for the latest status

Contact information:

Vanessa Fell M.A.

(507) 266-6068

Fell.Vanessa@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20584130

Mayo Clinic Footer